An exterior view of the head office of Janssen pharmaceutical company in Leiden, Netherlands.
Image: Niels Wenstedt/BSR Agency/Getty Images
Johnson & Johnson’s easy-to-deliver COVID-19 shot is the vaccine of choice for much of the developing world.
Yet the U.S. company, which has already fallen far behind on its deliveries to poorer countries, late last year quietly shut down the only plant making usable batches of the vaccine, according to people familiar with the decision.
The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus.
©2019 New York Times News Service